Pupyshev A. B.

Dr. Pupyshev A. B.

orcid

Research Focus & Metrics

Academic Career Length

54Years (1973-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Pupyshev A. B.Pupyshev A. B.
Pupyshev A. B.
AAAnna A. Akopyan
Anna A. Akopyan
MTMichael V. Tenditnik
Michael V. Tenditnik
MOMarina V. Ovsyukova
Marina V. Ovsyukova
NDNina I. Dubrovina
Nina I. Dubrovina
Maria A TikhonovaMaria A Tikhonova
Maria A Tikhonova
In the treatment of experimental neurodegeneration with disaccharide trehalose, various regimens are used, predominantly a 2% solution, drunk for several weeks. We studied the effects of different regimens of dietary trehalose treatment in an amyloid-β (Aβ) 25–35-induced murine model of Alzheimer’s disease (AD). Aβ-treated mice received 2% trehalose solution daily, 4% trehalose solution daily (continuous mode) or every other day (intermittent mode), to drink for two weeks. We revealed the dose-dependent effects on autophagy activation in the frontal cortex and hippocampus, and the restoration of behavioral disturbances. A continuous intake of 4% trehalose solution caused the greatest activation of autophagy and the complete recovery of step-through latency in the passive avoidance test that corresponds to associative long-term memory and learning. This regimen also produced an anxiolytic effect in the open field. The effects of all the regimens studied were similar in Aβ load, neuroinflammatory response, and neuronal density in the frontal cortex and hippocampus. Trehalose successfully restored these parameters to the levels of the control group. Thus, high doses of trehalose had increased efficacy towards cognitive impairment in a model of early AD-like pathology. These findings could be taken into account for translational studies and the development of clinical approaches for AD therapy using trehalose.

1 December 2023 in Neurochemical Journal
Verified
Journal Article
Closed access
PDF file
Pupyshev A. B.Pupyshev A. B.
Pupyshev A. B.
TKT. A. Korolenko
T. A. Korolenko
MTM. A. Tikhonova
M. A. Tikhonova
The search for effective treatment for neurodegeneration implies attacking the multiple mechanisms of this pathology. Such properties were found in disaccharide trehalose, which shows therapeutic effects in models of many diseases and has been approved by the FDA for use in humans. Trehalose consists of two glucose residues bonded together by a flexible α-1-1'-glycosidic bond, giving it chaperone-like activity. Due to this, it prevents abnormal folding of aberrant proteins and has the properties of a cryo- and bioprotector. However, the main therapeutic effect is determined by the induction of mTOR-independent autophagy mediated by AMPK kinase as the main target. The result is a weakening of the accumulation of cytotoxic proteins and factors and an increase in cell viability. Autophagy activation depends on trehalose-induced lysosome and autophagosome biogenesis through activation of transcription factors TFEB and FOXO1. Trehalose has an anti-inflammatory effect closely related to the inhibition of oxidative stress. Trehalose-induced enhancement of endogenous antioxidant defense involves the regulator Nrf2. The review considers the neuroprotective effects of trehalose in models of major neurodegenerative diseases such as Parkinson’s, Alzheimer’s, Huntington’s and others. Overall, trehalose shows high therapeutic potential in the treatment of experimental neurodegeneration and thus stimulating the study of its clinical application.

1 January 2005 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
Pupyshev A. B.Pupyshev A. B.
Pupyshev A. B.
EGE. M. Gutina
E. M. Gutina
RFR. G. Fedina
R. G. Fedina
SMS. V. Michurina
S. V. Michurina
ASA. V. Shurlygina
A. V. Shurlygina
LVL. V. Verbitskaya
L. V. Verbitskaya

1 October 2002 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
OGO. R. Grek
O. R. Grek
SMS. V. Mishenina
S. V. Mishenina
Pupyshev A. B.Pupyshev A. B.
Pupyshev A. B.

1 July 2003 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
OGO. R. Grek
O. R. Grek
Pupyshev A. B.Pupyshev A. B.
Pupyshev A. B.
ETE. V. Tikhonova
E. V. Tikhonova